Up­dat­ed: Eu­ro­pean reg­u­la­tors in­ves­ti­gat­ing 150 re­ports of self-in­jury, sui­cide risk in pa­tients tak­ing No­vo Nordisk meds for weight loss

The Eu­ro­pean Med­i­cines Agency is look­ing in­to about 150 re­ports of “pos­si­ble cas­es of self-in­jury and sui­ci­dal thoughts” for weight loss pa­tients who used No­vo Nordisk’s semaglu­tide or li­raglu­tide med­i­cines.

The first three case re­ports were flagged by mem­ber agency Ice­landic Med­i­cines Agency, un­veiled on Mon­day. The EMA’s safe­ty com­mit­tee, the Phar­ma­covig­i­lance Risk As­sess­ment Com­mit­tee (PRAC), is now in­ves­ti­gat­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.